The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
Brain metastases
Breast cancer
Predictive factors
Prognostic factors
Tau protein
Tumor markers
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Jan 2019
30 Jan 2019
Historique:
received:
03
04
2018
accepted:
07
01
2019
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
6
5
2019
Statut:
epublish
Résumé
Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient's outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. Tau, a microtubule-associated protein, is a neuronal marker that is also expressed in normal breast epithelial cells and cancer cells. Its tissue expression is associated with prognosis in MBC. However, the prognostic value of Tau serum levels in these patients is unknown. We aimed at evaluating the prognostic value of Tau (and other classical biomarkers) in MBC patients, and to assess its association with the presence of brain metastases (BM). 244 MBC patients treated at our institution (2007-2015) were retrospectively selected. The usual MBC clinical and pathological variables were collected, altogether with CA15-3, CEA and HER2 extra-cellular domain (ECD) serum levels. Tau serum levels were measured with a novel immunoassay (digital ELISA) using Single Molecule Array (Simoa) technology. Overall survival (OS) was estimated with the Kaplan-Meier method. To investigate prognostic factors, a multivariate analysis was performed. Cut-offs were set using the Youden index method associated with receiver-operating characteristics (ROC) curves to evaluate the accuracy of biomarkers to identify patients with BM. With a median follow-up of 40.8 months, median OS was 15.5 months (95%CI 12.4-20.2). Elevated serum levels of Tau were independently associated with a poor outcome in the whole population as well as in patients with (n = 86) and without BM (n = 158). Median serum Tau levels tended to be higher in patients with BM (p = 0.23). In univariate analysis, patients with BM had an increased risk of serum Tau > 3.17 pg/mL (OR = 2.2, p = 0.049). In multivariate analysis, high values of Tau (OR = 3.98, p = 0.034) accurately identified patients with BM in our cohort. Tau is a new biomarker of interest in MBC. Its serum level could represent an independent prognostic factor in these patients (both with and without BM). It also seems to be associated with the presence of BM. A validation of these results in an independent set of MBC patients is necessary to confirm these findings.
Sections du résumé
BACKGROUND
BACKGROUND
Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient's outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. Tau, a microtubule-associated protein, is a neuronal marker that is also expressed in normal breast epithelial cells and cancer cells. Its tissue expression is associated with prognosis in MBC. However, the prognostic value of Tau serum levels in these patients is unknown. We aimed at evaluating the prognostic value of Tau (and other classical biomarkers) in MBC patients, and to assess its association with the presence of brain metastases (BM).
METHODS
METHODS
244 MBC patients treated at our institution (2007-2015) were retrospectively selected. The usual MBC clinical and pathological variables were collected, altogether with CA15-3, CEA and HER2 extra-cellular domain (ECD) serum levels. Tau serum levels were measured with a novel immunoassay (digital ELISA) using Single Molecule Array (Simoa) technology. Overall survival (OS) was estimated with the Kaplan-Meier method. To investigate prognostic factors, a multivariate analysis was performed. Cut-offs were set using the Youden index method associated with receiver-operating characteristics (ROC) curves to evaluate the accuracy of biomarkers to identify patients with BM.
RESULTS
RESULTS
With a median follow-up of 40.8 months, median OS was 15.5 months (95%CI 12.4-20.2). Elevated serum levels of Tau were independently associated with a poor outcome in the whole population as well as in patients with (n = 86) and without BM (n = 158). Median serum Tau levels tended to be higher in patients with BM (p = 0.23). In univariate analysis, patients with BM had an increased risk of serum Tau > 3.17 pg/mL (OR = 2.2, p = 0.049). In multivariate analysis, high values of Tau (OR = 3.98, p = 0.034) accurately identified patients with BM in our cohort.
CONCLUSIONS
CONCLUSIONS
Tau is a new biomarker of interest in MBC. Its serum level could represent an independent prognostic factor in these patients (both with and without BM). It also seems to be associated with the presence of BM. A validation of these results in an independent set of MBC patients is necessary to confirm these findings.
Identifiants
pubmed: 30700265
doi: 10.1186/s12885-019-5287-z
pii: 10.1186/s12885-019-5287-z
pmc: PMC6354387
doi:
Substances chimiques
Biomarkers, Tumor
0
MAPT protein, human
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110Subventions
Organisme : SIRIC Montpellier Cancer
ID : INCa-DGOS-Inserm 6045
Références
Breast Cancer Res Treat. 2000 Feb;59(3):271-8
pubmed: 10832597
Leukemia. 2000 Dec;14(12):2076-84
pubmed: 11187896
Eur Neurol. 2002;47(1):45-51
pubmed: 11803192
Ann Oncol. 2001;12 Suppl 3:S15-9
pubmed: 11804378
Ann Emerg Med. 2002 Mar;39(3):254-7
pubmed: 11867977
Neurology. 2002 Jun 11;58(11):1622-8
pubmed: 12058089
J Alzheimers Dis. 2000 Nov;2(3-4):199-206
pubmed: 12214084
J Alzheimers Dis. 2002 Oct;4(5):375-98
pubmed: 12446970
JAMA. 2003 Apr 23-30;289(16):2094-103
pubmed: 12709467
Br J Cancer. 2003 Jul 21;89(2):284-90
pubmed: 12865918
J Neurol. 2004 Apr;251(4):414-20
pubmed: 15083285
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20
pubmed: 15914550
Clin Neurol Neurosurg. 2006 Sep;108(6):558-63
pubmed: 16457947
Breast Cancer Res Treat. 2006 Nov;100(2):229-35
pubmed: 16932852
Cancer. 2007 Sep 1;110(5):973-9
pubmed: 17647245
Eur J Paediatr Neurol. 2008 Jul;12(4):334-41
pubmed: 17951083
Ann Oncol. 2008 Dec;19(12):2012-9
pubmed: 18641006
J Clin Oncol. 2008 Aug 1;26(22):3660-2
pubmed: 18669447
Ann Oncol. 2009 Nov;20(11):1771-85
pubmed: 19608616
J Cell Biochem. 2009 Oct 15;108(3):555-64
pubmed: 19681044
J Clin Oncol. 2010 Jan 1;28(1):92-8
pubmed: 19933921
Jpn J Clin Oncol. 2010 Apr;40(4):286-93
pubmed: 20085902
Oncogene. 2010 Jun 3;29(22):3217-27
pubmed: 20228842
Nat Biotechnol. 2010 Jun;28(6):595-9
pubmed: 20495550
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
Cancer Treat Rev. 2012 Apr;38(2):133-42
pubmed: 21549508
Breast Cancer Res. 2011 Nov 02;13(5):R85
pubmed: 21888627
Cerebrovasc Dis. 2012;33(1):47-54
pubmed: 22133844
Breast Cancer Res. 2012 Feb 13;14(1):R29
pubmed: 22330883
Neuro Oncol. 2012 Sep;14(9):1171-7
pubmed: 22898372
Clin Cancer Res. 2012 Nov 15;18(22):6348-55
pubmed: 22952345
Breast Cancer Res Treat. 2013 Oct;141(3):477-84
pubmed: 24072270
Breast Cancer Res Treat. 2013 Oct;141(3):507-14
pubmed: 24104881
Ann Oncol. 2014 Mar;25(3):633-8
pubmed: 24368402
JAMA Neurol. 2014 Jul 1;71(7):926-7
pubmed: 25023557
J Clin Oncol. 2014 Nov 20;32(33):3753-61
pubmed: 25332247
Childs Nerv Syst. 2015 Aug;31(8):1313-9
pubmed: 25899850
J Clin Oncol. 2015 Jul 10;33(20):2239-45
pubmed: 25987700
PLoS One. 2015 Jul 24;10(7):e0133830
pubmed: 26207909
Anticancer Res. 2015 Oct;35(10):5179-84
pubmed: 26408675
BMC Cancer. 2016 Jul 07;16:428
pubmed: 27387327
Int J Cancer. 2016 Nov 15;139(10):2299-311
pubmed: 27464303
Breast. 2018 Feb;37:36-41
pubmed: 29073498
J Cell Biol. 1985 Oct;101(4):1371-8
pubmed: 3930508
Cancer. 1983 Dec 15;52(12):2349-54
pubmed: 6640506
J Clin Oncol. 1998 Jul;16(7):2401-8
pubmed: 9667257